128 related articles for article (PubMed ID: 19035274)
1. Use of an extracellular matrix material as a vaccine carrier and adjuvant.
Suckow MA; Hall P; Wolter W; Sailes V; Hiles MC
Anticancer Res; 2008; 28(5A):2529-34. PubMed ID: 19035274
[TBL] [Abstract][Full Text] [Related]
2. Immunization with a tissue vaccine enhances the effect of irradiation on prostate tumors.
Suckow MA; Wheeler J; Wolter WR; Sailes V; Yan M
In Vivo; 2008; 22(2):171-7. PubMed ID: 18468400
[TBL] [Abstract][Full Text] [Related]
3. Small intestinal submucosa does not promote PAIII tumor growth in Lobund-Wistar rats.
Hodde JP; Suckow MA; Wolter WR; Hiles MC
J Surg Res; 2004 Aug; 120(2):189-94. PubMed ID: 15234212
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of prostate cancer metastasis by administration of a tissue vaccine.
Suckow MA; Wolter WR; Sailes VT
Clin Exp Metastasis; 2008; 25(8):913-8. PubMed ID: 18821060
[TBL] [Abstract][Full Text] [Related]
5. Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine.
Suckow MA; Rosen ED; Wolter WR; Sailes V; Jeffrey R; Tenniswood M
Cancer Immunol Immunother; 2007 Aug; 56(8):1275-83. PubMed ID: 17242926
[TBL] [Abstract][Full Text] [Related]
6. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.
Mortara L; Frangione V; Castellani P; De Lerma Barbaro A; Accolla RS
Int Immunol; 2009 Jun; 21(6):655-65. PubMed ID: 19395374
[TBL] [Abstract][Full Text] [Related]
7. Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer.
Naruishi K; Timme TL; Kusaka N; Fujita T; Yang G; Goltsov A; Satoh T; Ji X; Tian W; Abdelfattah E; Men T; Watanabe M; Tabata K; Thompson TC
Cancer Gene Ther; 2006 Jul; 13(7):658-63. PubMed ID: 16485011
[TBL] [Abstract][Full Text] [Related]
8. Prevention of de novo prostate cancer by immunization with tumor-derived vaccines.
Suckow MA; Wolter WR; Pollard M
Cancer Immunol Immunother; 2005 Jun; 54(6):571-6. PubMed ID: 15685450
[TBL] [Abstract][Full Text] [Related]
9. Bropirimine as neoadjuvant therapy decreases residual disease and expression of markers PCNA and TGF-beta 1 in a rat orthotopic prostate adenocarcinoma.
Lievano G; Di Domenico D; Brown J; Bridges P; Rubenstein M; Shaw M; Guinan P
Methods Find Exp Clin Pharmacol; 1997 May; 19(4):261-7. PubMed ID: 9228652
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
11. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
Lubaroff DM; Karan D
Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of murine prostate cancer using whole tumour cells killed ex vivo by cytosine deaminase/5-fluorocytosine suicide-gene therapy.
Pandha HS; Cook D; Greenhalgh R; Dalgleish A
BJU Int; 2005 Jun; 95(9):1336-43. PubMed ID: 15892827
[TBL] [Abstract][Full Text] [Related]
13. Calcification potential of small intestinal submucosa in a rat subcutaneous model.
Owen TJ; Lantz GC; Hiles MC; VanVleet J; Martin BR; Geddes LA
J Surg Res; 1997 Aug; 71(2):179-86. PubMed ID: 9299288
[TBL] [Abstract][Full Text] [Related]
14. The antimetastatic effect of IV-inoculated BCG on adenocarcinomas in the prostate-seminal vesicle complex of L-W rats.
Pollard M; Luckert PH
Anticancer Res; 1994; 14(3A):901-3. PubMed ID: 8074491
[TBL] [Abstract][Full Text] [Related]
15. Tissue vaccines for cancer.
Suckow MA; Heinrich J; Rosen ED
Expert Rev Vaccines; 2007 Dec; 6(6):925-37. PubMed ID: 18377356
[TBL] [Abstract][Full Text] [Related]
16. Cryosurgical ablation of the normal ventral prostate plus adjuvant does not protect Copenhagen rats from Dunning prostatic adenocarcinoma challenge.
Friedman EJ; Orth CR; Brewton KA; Ponniah S; Alexander RB
J Urol; 1997 Oct; 158(4):1585-8. PubMed ID: 9302178
[TBL] [Abstract][Full Text] [Related]
17. Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope.
Lu Y; Ouyang K; Fang J; Zhang H; Wu G; Ma Y; Zhang Y; Hu X; Jin L; Cao R; Fan H; Li T; Liu J
Vaccine; 2009 Aug; 27(39):5411-8. PubMed ID: 19616501
[TBL] [Abstract][Full Text] [Related]
18. Use of Conditioned Extracellular Matrix as a Tissue-engineered Tumor Matrisome for Prostate Cancer and Melanoma Immunotherapy.
Suckow MA; Hiles MC
Anticancer Res; 2023 Jan; 43(1):335-341. PubMed ID: 36585187
[TBL] [Abstract][Full Text] [Related]
19. A comparative analysis of expanded polytetrafluoroethylene and small intestinal submucosa--implications for patch repair in ventral herniorrhaphy.
Rauth TP; Poulose BK; Nanney LB; Holzman MD
J Surg Res; 2007 Nov; 143(1):43-9. PubMed ID: 17950071
[TBL] [Abstract][Full Text] [Related]
20. Bupivacaine-enhanced small intestinal submucosa biomaterial as a hernia repair device.
Suckow MA; Wolter WR; Fecteau C; Labadie-Suckow SM; Johnson C
J Biomater Appl; 2012 Aug; 27(2):231-7. PubMed ID: 21680611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
